Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases - Cancer Currents Blog

The latest from the NCI Cancer Currents blog

Having trouble viewing this email? View it as a Web page.

Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases 07/10/2024 Lorlatinib (Lorbrena) is superior to crizotinib (Xalkori) as an initial treatment for people with ALK-positive advanced non-small cell lung cancer, according to new clinical trial results. Treatment with lorlatinib also helped prevent new brain metastases. You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp  Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892